Categories: Funding

Alios BioPharma Raises $41M in Series B

Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for respiratory viral diseases, today announced it has completed a $41 Million Series B financing. All existing investors — Novo Ventures, SR One, Roche Venture Fund and Novartis Ventures — participated in this round, which was led by a new, undisclosed investor.

‘We are pleased to welcome our newest investor and to have the continued support from our current investors for this round of financing,’ stated Lawrence M. Blatt, PhD, President and Chief Executive Officer of Alios BioPharma. ‘This funding will allow Alios to retain ownership and control of our novel, first-in-class anti-respiratory virus development programs.’

Proceeds from this financing will be used primarily to support continued clinical development of Alios’ respiratory portfolio, including AL-8176, an anti-RSV nucleoside analog now in Phase 2 clinical development, and multiple late-stage preclinical development programs targeting Influenza and Rhinovirus.

Alios successfully completed Phase 1 testing of AL-8176 in healthy volunteers in 2013. The company is currently conducting two clinical studies in RSV-infected individuals. The first study is a Phase 2a clinical trial designed to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of AL-8176 against respiratory syncytial virus (RSV) infection in a virus challenge study. The second study comprises a single ascending dose clinical trial in infants hospitalized with RSV infection that is also examining safety, pharmacokinetics and antiviral activity.

About Alios
Alios BioPharma is a privately-held biotechnology company located in South San Francisco, CA, that is developing novel medicines aimed at the treatment of viral diseases. Alios has an innovative team of highly experienced scientists and clinical researchers who are developing direct acting antiviral agents against several human viral pathogens of public health importance including respiratory viruses, and other chronic, acute and emerging viral diseases. The overall goal for the Alios therapeutic platform is to maximize patient benefits in areas of high unmet medical need through optimization of potency, safety and tolerability. For more information please visit www.aliosbiopharma.com.

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Alios%20BioPharma/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co

Arpit Jain

Based in Japan and India. Has led to 1 successful fundraise in Japan. Been working the space of Venture Capital and Private Equity for the last 3 years.

Leave a Comment
Share
Published by
Tags: INVC

Recent Posts

Commentary on HealthTech Startups in Singapore

Singapore has always had a progressive healthcare system with prioritizing innovative solutions to the existing…

3 years ago

What are Ponzi Schemes?

A Ponzi scheme is a fraudulent investment scheme that aims to give its investors high…

3 years ago

Commentary on Prop Tech in China

According to the Global Prop tech Survey, 2019 published by KPMG one of the key…

3 years ago

How do shell companies operate?

In April 2016, the world witnessed one of the biggest information leaks in history, consisting…

3 years ago

Singapore based cybersecurity company Silent Eight raises $8.8M

Silent Eight a global technology company that helps combat money laundering and terrorism financing using…

3 years ago

Retail-tech startup Gully Network Raises $1.2 Million

Indian startup Gully Network Retail Pvt Ltd, a retail-tech startup focused on providing services to…

3 years ago